Gå til indhold, Åbn navigation eller Gå til kontaktoplysninger.

Indstillinger

Neodynamics

0,449 SEK -1,21 %

HC Andersen Capital modtager betaling fra Neodynamics for en Digital IR/Corporate Visibility abonnementsaftale. Læs mere her.

6 investorer følger denne virksomhed

www.neodynamics.com/sv-se/investerare

NeoDynamics AB (publ) is a Swedish Medical Technology Company dedicated to advancing diagnosis and care of breast cancer. The company’s first product NeoNavia®, a new innovative pulse biopsy system for ultrasound guided tissue sampling, is currently being introduced to the market. The biopsy system is built on a patented pulse technology, based on research at the Karolinska Institutet in Sweden.

Omsætning

140 t

EBIT %

-52.307,14 %

P/E

-

Udbytteafkast, %

-

Kursmål

-

Anbefaling

-

Opdateret

-

First North Stockholm

NEOD

Daglig lav / høj pris

0,42 / 0,48 SEK

Markedsværdi

54,11 mio. SEK

Aktieomsætning

224,94 t SEK

Volumen

503 t

Seneste analyser

NeoDynamics - Equity Research Report - Company sponsored

Analyst

CEO, Sweden

Seneste videoer

NeoDynamics - Presentation of Q1 interim report 2023

NeoDynamics – Management elaborates on options for long-term financing

NeoDynamics - Presentation of Annual Accounts 2022

Finanskalender

Delårsrapport

17.08.2023

Delårsrapport

16.11.2023

Årsrapport

16.02.2024

Forum opdateringer

Hold dig opdateret med den seneste information fra Neodynamics

Læs hele tråden

Besøg forummet

NeoDynamics AB meddelte i går, at det indgår partnerskab med den globale distributions- og logistikgigant Uniphar Group for at sikre en succesfuld lancering af NeoNavia® i USA, dets innovative pulsbiopsisystem. NeoDynamics couldn’t be more pleased to be partnering with Uniphar, a proven global partner to pharma and MedTech companies. Leveraging Uniphar’s customer service, logistics management and digital technology will allow us to aggressively hit the US market. The relationship with Uniphar is a key corporate development as we put all the pieces in place for the successful US launch of NeoNavia, fortæller Anna Eriksrud CEO af NeoDynamics. Endnu et vigtig skridt for NeoDynamics i forbindelse med deres lancering af puls biopsi-systemet Neonavia på det amerikanske marked. Efter FDA godkendelsen i efteråret 2022 er der kommet fart på forberedelserne op til lanceringen. De har fået ledelse, partner til hjælp med lanceringen og nu også en distributionspartner på plads. Det totale marked for bryst biopsi vurderes til USD 830 mio. i 2025. Læs hele meddelelsen her.

Olivier A. de Goeij

for 4 måneder siden💙 1

Husk at læse hele vores research disclaimer på https://www.inderes.dk/disclaimer. Dansk: NeoDynamics AB (publ) er en svensk medicinsk teknologivirksomhed dedikeret til at fremme diagnosticering og behandling af brystkræft. Virksomhedens første produkt NeoNavia®, et nyt innovativt pulsbiopsisystem til ultralydsstyret vævsprøvetagning, er i øjeblikket ved at blive introduceret på markedet. Biopsisystemet er bygget på en patenteret pulsteknologi, baseret på forskning ved Karolinska Institutet i Sverige. NeoNavia er evalueret for brystkræftdiagnose på førende klinikker i Storbritannien, Tyskland og Sverige. Pulsbiopsisystemet er blevet brugt til vævsprøvetagning i bryst og aksillære lymfer hos over 500 patienter. English: NeoDynamics AB (publ) is a Swedish Medical Technology Company dedicated to advancing the diagnosis and care of breast cancer. The company’s first product NeoNavia®, a new innovative pulse biopsy system for ultrasound-guided tissue sampling, is currently being introduced to the market. The biopsy system is built on a patented pulse technology, based on research at the Karolinska Institutet in Sweden. NeoNavia is evaluated for breast cancer diagnosis at leading clinics in UK, Germany, and Sweden. The pulse biopsy system has been used for tissue sampling in the breast and axilla in over 500 patients.

Olivier A. de Goeij

for 7 måneder siden

Viser Alle indholdstyper

Bulletin from the annual general meeting in NeoDynamics AB (publ)

Selskabsmeddelelse23.05.2023

NeoDynamics - Presentation of Q1 interim report 2023

Meet CFO Aaron Wong who will give an update on the Q1 results and further dive into the development for NeoNavia in Europe. The event takes place Friday the 12th of May at 10.00 AM.

Videopræsentation12.05.2023

Redeye: NeoDynamics Q1 2023 - Continues its US launch

Pressemeddelelse12.05.2023

NeoDynamics AB (publ) first quarter 2023

Selskabsmeddelelse11.05.2023

Fast comment - NeoDynamics present at The SBI Breast Imaging Symposium

NeoDynamics present final data set from the PULSE Study at The SBI Breast Imaging Symposium....

Analytikerkommentar05.05.2023 af Claus Thestrup

Final data set from NeoDynamics’ PULSE study presented at The SBI Breast Imaging Symposium

Pressemeddelelse05.05.2023

NeoDynamics publishes Annual Report 2022

NeoDynamics has published their annual report for the financial year 2022.

Analytikerkommentar03.05.2023 af Claus Thestrup

NeoDynamics publishes Annual Report 2022

Selskabsmeddelelse02.05.2023

Notice of Annual General Meeting in NeoDynamics

The shareholders in NeoDynamics have been conveyed to the annual general meeting on Tuesday 23 May 2023 at 15.00 at the Company’s premises at Lejonvägen 14, Lidingö.

Analytikerkommentar25.04.2023 af Claus Thestrup

Notice of Annual General Meeting in NeoDynamics AB (Publ)

Selskabsmeddelelse24.04.2023

Dagens aktienyheder 04/04

MapsPeople har i en pressemeddelelse annonceret en udvidelse af selskabets kortlægningsmuligheder. NeoDynamics gave yesterday an update on delivery of needles in Europe and US. NeoDynamics : The Extraordinary General Meeting. Qlife: The nomination committee’s proposal for new board members.

Analytikerkommentar04.04.2023

MapsPeople Neodynamics Qlife Holding

Bulletin from Extraordinary General Meeting in NeoDynamics AB (publ)

Selskabsmeddelelse03.04.2023

Dagens aktienyheder 17/03

BioPorto A/S’s aktier faldt knap 11 procent i går efter at selskabet udsendte en update. Odico A/S har modtaget en ny ordre inden for forretningsområdet Digital Fabrikation. Ascelia Pharma AB afholdt tidligere på ugen et kapitalmarkedsevent. One-pager på Shape Robotics. NeoDynamics : Interview with CEO Anna Eriksrud and Aaron Wong FCCA

Analytikerkommentar17.03.2023

BioPorto Odico Ascelia Pharma Shape Robotics

NeoDynamics: Management elaborates on options for long-term financing

We hosted an event Wednesday the 15th of March with CEO Anna Eriksrud and CFO Aaron Wong on funding as is and to be.

Analytikerkommentar16.03.2023 af Claus Thestrup

NeoDynamics – Management elaborates on options for long-term financing

Meet CEO Anna Eriksrud and CFO Aaron Wong who will elaborate on options to raise long-term capital to enable the commercialization of NeoNavia in the US. The event takes place Wednesday the 15th. of March 2.00 PM.

Videopræsentation15.03.2023

HC Andersen Capital: NeoDynamics' Management elaborates on options for long-term financing

Pressemeddelelse13.03.2023

Dagens aktienyheder 07/03

Skjern Bank handler i dag ex. udbytte på DKK 3 pr. aktie. NeoDynamics meddelte i går, at man nu også har fået patent på sit FlexiPulse produkt i Kina. Pharma Equity Group A/S er nyt dansk biotek selskab.

Analytikerkommentar07.03.2023

Skjern Bank Neodynamics Pharma Equity Group

NeoDynamics is investigating options to raise long-term capital to enable commercialization of NeoNavia in the US

Analytikerkommentar01.03.2023 af Claus Thestrup

Dagens aktienyheder 01/03

Green Hydrogen Systems er her til morgen ude med årsrapporten for 2022. Re-Match melder her til morgen, at de har til hensigt at lade sig afnotere. Bavarian Nordic, der i 2022 påbegyndte et fase 3 studie af sin RSV-vaccine kandidat, og forventer foreløbige resultater i midten af 2023. Event med Hafnia. NeoDynamics investigate options to raise longterm financing.

Analytikerkommentar01.03.2023

Green Hydrogen Systems Re-Match Bavarian Nordic Neodynamics

Notice of extraordinary general meeting in NeoDynamics AB (publ)

Selskabsmeddelelse01.03.2023